Vol. 6 No. 2 (2026)
Reimbursement Reviews

Mirvetuximab Soravtansine (Elahere)

decorative image of the issue cover

Published February 25, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses mirvetuximab soravtansine (Elahere), 5 mg/mL, concentrate for solution for injection, IV infusion.
  • Indication: As monotherapy indicated for the treatment of adult patients with folate receptor (FR-alpha) alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received 1 to 3 prior systemic treatment regimens.